NCT03868072View on ClinicalTrials.gov

"Study to Evaluate the Bioequivalence of Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

March 29, 2019

Study Completion Date

April 20, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

XELJANZ 5Mg Tablet

XELJANZ 5Mg Tablet 1T single oral administration under fasting

DRUG

Chong Kun Dang Tofacitinib Tablet

Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting

Trial Locations (1)

Unknown

Bestian Hospital, Osŏng

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY